Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Raw Materials (2016 - 2018)

Anika Therapeutics (ANIK) has disclosed Raw Materials for 8 consecutive years, with $13.2 million as the latest value for Q3 2018.

  • Quarterly Raw Materials rose 68.31% to $13.2 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Sep 2018, up 68.31% year-over-year, with the annual reading at $11.3 million for FY2017, 91.98% up from the prior year.
  • Raw Materials for Q3 2018 was $13.2 million at Anika Therapeutics, up from $12.6 million in the prior quarter.
  • The five-year high for Raw Materials was $13.2 million in Q3 2018, with the low at $4.9 million in Q3 2015.
  • Average Raw Materials over 5 years is $7.4 million, with a median of $6.3 million recorded in 2017.
  • The sharpest move saw Raw Materials decreased 28.96% in 2015, then soared 100.13% in 2018.
  • Over 5 years, Raw Materials stood at $6.2 million in 2014, then fell by 6.2% to $5.8 million in 2015, then rose by 1.8% to $5.9 million in 2016, then surged by 91.98% to $11.3 million in 2017, then grew by 17.22% to $13.2 million in 2018.
  • According to Business Quant data, Raw Materials over the past three periods came in at $13.2 million, $12.6 million, and $10.1 million for Q3 2018, Q2 2018, and Q1 2018 respectively.